폐동맥 고혈압 시장 보고서(2026년)

Pulmonary arterial hypertension is a condition characterized by abnormally high blood pressure that damages the arteries in the lungs and the right side of the heart. In this chronic and progressive disorder, the walls of the pulmonary arteries become narrowed and stiff. Drugs used to treat pulmonary arterial hypertension work by relaxing the muscles in blood vessel walls, improving blood flow through the lungs, or counteracting substances that cause blood vessels to constrict.

The primary classes of pulmonary arterial hypertension drugs include endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5) inhibitors, prostacyclin and prostacyclin analogs, and soluble guanylate cyclase (sGC) stimulators. Endothelin receptor antagonists are a type of targeted therapy used to treat patients with pulmonary hypertension, helping to slow disease progression and potentially reverse certain aspects of heart and lung damage. These drugs are administered via oral, intravenous or subcutaneous, and inhalational routes, and are distributed through retail and online channels.

Tariffs have affected the pulmonary arterial hypertension market by increasing import costs for active pharmaceutical ingredients and advanced drug delivery systems. The oral and prostacyclin drug segments, particularly in regions like Asia-Pacific and Latin America, are most impacted due to dependency on imported raw materials. While tariffs raise production costs and may limit access in certain markets, they also encourage local manufacturing investments and innovation in cost-efficient drug formulations, potentially improving regional self-sufficiency and long-term market resilience.

The pulmonary arterial hypertension market research report is one of a series of new reports from The Business Research Company that provides pulmonary arterial hypertension market statistics, including pulmonary arterial hypertension industry global market size, regional shares, competitors with a pulmonary arterial hypertension market share, detailed pulmonary arterial hypertension market segments, market trends and opportunities, and any further data you may need to thrive in the pulmonary arterial hypertension industry. This pulmonary arterial hypertension market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pulmonary arterial hypertension market size has grown strongly in recent years. It will grow from $9.15 billion in 2025 to $9.94 billion in 2026 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to rising prevalence of pulmonary arterial hypertension, limited early diagnosis capabilities, high unmet medical needs, availability of conventional drugs, growing awareness among healthcare professionals.

The pulmonary arterial hypertension market size is expected to see strong growth in the next few years. It will grow to $13.75 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to development of novel therapies, expansion of telemedicine, increasing government healthcare initiatives, rising adoption of combination therapies, growth in specialized treatment centers. Major trends in the forecast period include personalized pulmonary hypertension therapies, advanced drug delivery systems, combination therapy development, telehealth and remote patient monitoring, emerging regional treatment centers.

The growing number of clinical trials for drug development is expected to support the growth of the pulmonary arterial hypertension market in the coming years. Clinical trials are research studies carried out to assess the safety, efficacy, and potential side effects of new drugs or therapeutic approaches in humans. An increase in clinical trials targeting pulmonary arterial hypertension can result in the development of more effective treatment options, improvements in patient quality of life, enhanced safety and efficacy outcomes, earlier access to innovative therapies, and the identification of more cost-effective treatments. For example, in May 2023, according to Xtalks, a Canada-based provider of life science webinars and virtual events, a total of 452,604 clinical studies were registered on ClinicalTrials.gov as of May 17, 2023, with 64,838 studies actively recruiting participants. Therefore, the rising number of clinical trials for drug development is contributing to the expansion of the pulmonary arterial hypertension market.

Major companies operating in the pulmonary arterial hypertension market are introducing advanced therapies, such as OPSYNVI, to offer improved treatment options that enhance patient outcomes and quality of life for individuals affected by this serious condition. For instance, in March 2024, Johnson & Johnson, a US-based multinational company specializing in pharmaceuticals, biotechnology, and medical technologies, launched OPSYNVI for the long-term treatment of adults with pulmonary arterial hypertension. OPSYNVI is indicated for patients who are either newly diagnosed or already receiving therapy with an endothelin receptor antagonist (ERA), a phosphodiesterase-5 (PDE5) inhibitor, or both. It is also appropriate for patients maintained on stable doses of macitentan 10 mg and tadalafil 40 mg administered as separate tablets.

In May 2024, Gossamer Bio, a US-based biopharmaceutical company focused on treatments for pulmonary arterial hypertension (PAH), entered into a partnership with Chiesi Farmaceutici S.p.A. Through this collaboration, both companies aim to combine their expertise to enhance the treatment of pulmonary arterial hypertension and accelerate the development of therapies for pulmonary hypertension associated with interstitial lung disease (PH-ILD). Chiesi Farmaceutici S.p.A. is an Italy-based pharmaceutical company.

Major companies operating in the pulmonary arterial hypertension market are United Therapeutics Corporation, Acceleron Pharma Inc., Actelion Pharmaceuticals US Inc., Bayer AG, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Liquidia Technologies Inc., Lupin Pharmaceuticals Inc., Natco Pharma Ltd., Pfizer Inc., Sandoz AG, Teva Pharmaceutical Industries Ltd., Zydus Pharmaceutical USA Inc., Merck KGaA, Novartis International AG, Bristol-Myers Squibb Company, AstraZeneca plc, Daiichi Sankyo Company Limited

North America was the largest region in the pulmonary arterial hypertension market in 2025. The regions covered in the pulmonary arterial hypertension market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the pulmonary arterial hypertension market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pulmonary arterial hypertension market includes revenues earned by entities by idiopathic, heritable, and drug and toxin-induced. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pulmonary Arterial Hypertension Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses pulmonary arterial hypertension market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pulmonary arterial hypertension ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pulmonary arterial hypertension market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Class: Endothelin Receptor Antagonists (ERAs); PDE-5 Inhibitors; Prostacyclin and Prostacyclin Analogs; SGC Stimulators
• 2) By Route Of Administration: Oral; Intravenous Or subcutaneous; Inhalational
• 3) By Distribution channel: Retail; Online
• Subsegments:
• 1) By Endothelin Receptor Antagonists (ERAs): Bosentan; Ambrisentan; Macitentan
• 2) By PDE-5 Inhibitors: Sildenafil; Tadalafil
• 3) By Prostacyclin And Prostacyclin Analogs: Epoprostenol; Treprostinil; Iloprost
• 4) By SGC Stimulators: Riociguat; Vericiguat
• Companies Mentioned: United Therapeutics Corporation; Acceleron Pharma Inc.; Actelion Pharmaceuticals US Inc.; Bayer AG; Eli Lilly and Company; Gilead Sciences Inc.; GlaxoSmithKline plc; Johnson & Johnson; Liquidia Technologies Inc.; Lupin Pharmaceuticals Inc.; Natco Pharma Ltd.; Pfizer Inc.; Sandoz AG; Teva Pharmaceutical Industries Ltd.; Zydus Pharmaceutical USA Inc.; Merck KGaA; Novartis International AG; Bristol-Myers Squibb Company; AstraZeneca plc; Daiichi Sankyo Company Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Pulmonary Arterial Hypertension Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Pulmonary Arterial Hypertension Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Pulmonary Arterial Hypertension Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Pulmonary Arterial Hypertension Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
  • 4.1.5 Artificial Intelligence & Autonomous Intelligence
• 4.2. Major Trends
  • 4.2.1 Personalized Pulmonary Hypertension Therapies
  • 4.2.2 Advanced Drug Delivery Systems
  • 4.2.3 Combination Therapy Development
  • 4.2.4 Telehealth and Remote Patient Monitoring
  • 4.2.5 Emerging Regional Treatment Centers

5. Pulmonary Arterial Hypertension Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Specialty Clinics
• 5.3 Ambulatory Care Centers
• 5.4 Home Healthcare Providers
• 5.5 Research & Academic Institutions

6. Pulmonary Arterial Hypertension Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Pulmonary Arterial Hypertension Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Pulmonary Arterial Hypertension PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Pulmonary Arterial Hypertension Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Pulmonary Arterial Hypertension Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Pulmonary Arterial Hypertension Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Pulmonary Arterial Hypertension Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Pulmonary Arterial Hypertension Market Segmentation

• 9.1. Global Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators
• 9.2. Global Pulmonary Arterial Hypertension Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Intravenous Or subcutaneous, Inhalational
• 9.3. Global Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Retail, Online
• 9.4. Global Pulmonary Arterial Hypertension Market, Sub-Segmentation Of Endothelin Receptor Antagonists (ERAs), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Bosentan, Ambrisentan, Macitentan
• 9.5. Global Pulmonary Arterial Hypertension Market, Sub-Segmentation Of PDE-5 Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Sildenafil, Tadalafil
• 9.6. Global Pulmonary Arterial Hypertension Market, Sub-Segmentation Of Prostacyclin And Prostacyclin Analogs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Epoprostenol, Treprostinil, Iloprost
• 9.7. Global Pulmonary Arterial Hypertension Market, Sub-Segmentation Of SGC Stimulators, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Riociguat, Vericiguat

10. Pulmonary Arterial Hypertension Market Regional And Country Analysis

• 10.1. Global Pulmonary Arterial Hypertension Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Pulmonary Arterial Hypertension Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Pulmonary Arterial Hypertension Market

• 11.1. Asia-Pacific Pulmonary Arterial Hypertension Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Pulmonary Arterial Hypertension Market

• 12.1. China Pulmonary Arterial Hypertension Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Pulmonary Arterial Hypertension Market

• 13.1. India Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Pulmonary Arterial Hypertension Market

• 14.1. Japan Pulmonary Arterial Hypertension Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Pulmonary Arterial Hypertension Market

• 15.1. Australia Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Pulmonary Arterial Hypertension Market

• 16.1. Indonesia Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Pulmonary Arterial Hypertension Market

• 17.1. South Korea Pulmonary Arterial Hypertension Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Pulmonary Arterial Hypertension Market

• 18.1. Taiwan Pulmonary Arterial Hypertension Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Pulmonary Arterial Hypertension Market

• 19.1. South East Asia Pulmonary Arterial Hypertension Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Pulmonary Arterial Hypertension Market

• 20.1. Western Europe Pulmonary Arterial Hypertension Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Pulmonary Arterial Hypertension Market

• 21.1. UK Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Pulmonary Arterial Hypertension Market

• 22.1. Germany Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Pulmonary Arterial Hypertension Market

• 23.1. France Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Pulmonary Arterial Hypertension Market

• 24.1. Italy Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Pulmonary Arterial Hypertension Market

• 25.1. Spain Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Pulmonary Arterial Hypertension Market

• 26.1. Eastern Europe Pulmonary Arterial Hypertension Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Pulmonary Arterial Hypertension Market

• 27.1. Russia Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Pulmonary Arterial Hypertension Market

• 28.1. North America Pulmonary Arterial Hypertension Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Pulmonary Arterial Hypertension Market

• 29.1. USA Pulmonary Arterial Hypertension Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Pulmonary Arterial Hypertension Market

• 30.1. Canada Pulmonary Arterial Hypertension Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Pulmonary Arterial Hypertension Market

• 31.1. South America Pulmonary Arterial Hypertension Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Pulmonary Arterial Hypertension Market

• 32.1. Brazil Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Pulmonary Arterial Hypertension Market

• 33.1. Middle East Pulmonary Arterial Hypertension Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Pulmonary Arterial Hypertension Market

• 34.1. Africa Pulmonary Arterial Hypertension Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Pulmonary Arterial Hypertension Market Regulatory and Investment Landscape

36. Pulmonary Arterial Hypertension Market Competitive Landscape And Company Profiles

• 36.1. Pulmonary Arterial Hypertension Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Pulmonary Arterial Hypertension Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Pulmonary Arterial Hypertension Market Company Profiles
  • 36.3.1. United Therapeutics Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Acceleron Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Actelion Pharmaceuticals US Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

37. Pulmonary Arterial Hypertension Market Other Major And Innovative Companies

• Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Liquidia Technologies Inc., Lupin Pharmaceuticals Inc., Natco Pharma Ltd., Pfizer Inc., Sandoz AG, Teva Pharmaceutical Industries Ltd., Zydus Pharmaceutical USA Inc., Merck KGaA, Novartis International AG, Bristol-Myers Squibb Company, AstraZeneca plc, Daiichi Sankyo Company Limited

38. Global Pulmonary Arterial Hypertension Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Pulmonary Arterial Hypertension Market

40. Pulmonary Arterial Hypertension Market High Potential Countries, Segments and Strategies

• 40.1 Pulmonary Arterial Hypertension Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Pulmonary Arterial Hypertension Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Pulmonary Arterial Hypertension Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer